PMS-CANDESARTAN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
12-10-2016
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
CANDESARTAN CILEXETIL
から入手可能:
PHARMASCIENCE INC
ATCコード:
C09CA06
INN（国際名）:
CANDESARTAN
投薬量:
4MG
医薬品形態:
TABLET
構図:
CANDESARTAN CILEXETIL 4MG
投与経路:
ORAL
パッケージ内のユニット:
30/100
処方タイプ:
Prescription
治療領域:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
製品概要:
Active ingredient group (AIG) number: 0135220001; AHFS:
認証ステータス:
APPROVED
承認日:
2012-08-03
製品の特徴
_pms-CANDESARTAN Product Monograph_
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
PMS-CANDESARTAN
Candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
PHARMASCIENCE INC.
6111 Av. Royalmount, Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
JULY 19, 2016
Submission Control No: 195306
_pms-CANDESARTAN Product Monograph_
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND
ADMINISTRATION..............................................................................
16
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
.........................................................................................................
24
完全なドキュメントを読む
